RecruitingPhase 2NCT06231381

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

A Phase II, Multicenter, Double-blind, Randomized, Placebo Parallel-controlled Trial to Evaluate the Efficacy and Safety of HB0034 in Patients with GPP Presenting with an Acute Flare of Moderate to Severe Intensity

Sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Enrollment

33 participants

Start Date

Feb 29, 2024

Study Type

INTERVENTIONAL

Conditions

Generalized Pustular Psoriasis (GPP)

Summary

This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HB0034 and Placebo for people with generalized pustular psoriasis (gpp). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHB0034

Anti-IL-36R antibody

OTHERPlacebo

non-biologically active drug

Locations(2)

Peking University People's Hospital (PKUPH)

Beijing, China

Shanghai Huaota Biopharmaceutical Co., Ltd

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06231381